Treatment for myopathy depends heavily on the underlying cause and the specific type of myopathy.
At Concord Stem Cell Limited, we are actively involved in research and development of advanced cellular therapies that may offer new avenues for treatment, particularly for conditions with limited traditional options.
Traditional and emerging treatment approaches include:
Medications:
Corticosteroids and Immunosuppressants: For inflammatory myopathies to suppress the overactive immune system.
Disease-Modifying Therapies (DMTs): For specific genetic myopathies to target the underlying molecular defect.
Enzyme Replacement Therapy: For certain metabolic myopathies.
Physical Therapy and Occupational Therapy: To maintain muscle strength, improve range of motion, and help with daily activities.
Supportive Care:
Pain Management: To alleviate muscle pain and cramps.
Respiratory Support: For individuals with respiratory muscle weakness.
Lifestyle Modifications: Regular, appropriate exercise (as guided by a physician), and avoiding triggers that worsen symptoms.
Concord Stem Cell Limited and Regenerative Medicine:
At Concord Stem Cell Limited,
we are at the forefront of regenerative medicine in Bangladesh.
Our cGMP-certified facility is dedicated to producing high-quality autologous and allogeneic stem cell products. While not a direct cure for all myopathies, stem cell therapies, particularly with Human Umbilical Cord Mesenchymal Stem Cells (hUC-MSC), are being extensively researched for their potential to:
Reduce Inflammation: MSCs possess potent immunomodulatory properties that can help dampen the inflammatory response seen in inflammatory myopathies.
Promote Muscle Regeneration: MSCs have the capacity to differentiate into various cell types, including muscle cells, and can release growth factors that support tissue repair and regeneration.
Improve Muscle Function: By fostering a healthier cellular environment and potentially replacing damaged muscle cells, stem cell therapies aim to improve muscle strength and function.
We offer various products derived from our cGMP facility, including Human Umbilical Cord Mesenchymal Stem Cell (hUC-MSC), Stromal Vascular Fraction, Bone Marrow Concentrate, Bone Marrow Mononuclear Cell, Platelet Rich Plasma, Peripheral Blood Stem Cell, Platelet Lysate, Platelet Rich Fibrin, and Injectable Platelet Rich Fibrin.
These advanced therapies, under strict medical guidance, represent a promising future in addressing the challenges of myopathic conditions.